Clinical Development

Our objective is the development of pharmaceutical specialties aimed at treating the major respiratory allergies. In the longer term, the potential benefits of allergen immunotherapy in other areas, such as in new indications through new technologies is being assessed. Our current research includes:

*HDM: House Dust Mite